Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

ALXO
ALX Oncology Holdings Inc. Common Stock
stock NASDAQ

At Close
May 8, 2025 3:59:34 PM EDT
0.4500USD-6.197%(-0.0300)840,295
0.00Bid   0.00Ask   0.0000Spread
Pre-market
May 8, 2025 8:54:30 AM EDT
0.4699USD-2.933%(-0.0142)1,449
After-hours
May 8, 2025 4:00:30 PM EDT
0.4602USD+1.612%(+0.0073)256
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 28, 2022
08:21AM EST  The Daily Biotech Pulse: Biogen Liquidates Out Of Biosimilar JV, Provention Bio Plots Diabetes Drug Resubmission, Merck Finds COVID Pill Effective Against Omicron   Benzinga
08:03AM EST  ALX Oncology's Evorpacept Gets Orphan Drug Tag For Gastric Cancer   Benzinga
Jan 27, 2022
10:16PM EST  ALX Oncology Holdings Inc. (ALXO) said that the U.S. Food and Drug Administration granted orphan drug designation to evorpacept, a next-generation CD47 blocker, for the treatment of patients with gastric cancer and gastroesophageal junction cancer.   RTTNews
05:52PM EST  ALX Oncology Confirms Earlier Report FDA Grants Orphan Drug Designation For Co's Evorpacept   Benzinga
12:09PM EST  ALX Oncology Granted Orphan Drug Designation For 'Treatment for gastric cancer and gastro-esophageal junction cancer'   Benzinga
Jan 10, 2022
06:22AM EST  ALX Oncology Provides Corporate Update And Highlights Key Milestones In 2022   RTTNews
06:00AM EST  ALX Oncology Holdings Inc., (ALX Oncology) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today provided a corporate update and highlighted key milestones anticipated in 2022.   GlobeNewswire Inc
Jan 4, 2022
07:00AM EST  ALX Oncology Holdings Inc., (ALX Oncology) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint pathway, today announced that Jaume Pons, Ph.D., Founder, President and Chief Executive Officer, will virtually present a company overview at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11 at 10:30 am ET.   GlobeNewswire Inc
Dec 22, 2021
10:07AM EST  Benzinga's Top Ratings Upgrades, Downgrades For December 22, 2021   Benzinga
07:51AM EST  10 Biggest Price Target Changes For Wednesday   Benzinga
05:36AM EST  Jefferies Downgrades ALX Oncology Holdings to Hold, Lowers Price Target to $25   Benzinga
Dec 14, 2021
09:01AM EST  DURECT Corporation Expands Board of Directors with Appointment of   PR Newswire
Dec 12, 2021
10:06AM EST  ALX Oncology Announced Initial Data from ASPEN-02, the Ongoing Phase 1 / 2 Study of Evorpacept in Combination with Azacitidine at ASH 2021; Said Complete Remissions With Cytogenetic Responses, Hematologic Improvement, and Transfusion Independence Were Observed in Patients With Previously Untreated Higher-risk MDS   Benzinga
09:00AM EST  -- Complete remissions with cytogenetic responses, hematologic improvement, and transfusion independence were observed in patients with previously untreated higher-risk MDS   GlobeNewswire Inc
Nov 11, 2021
04:30PM EST  ALX Oncology Holdings Q3 EPS $(0.61) Down From $(0.31) YoY   Benzinga
04:05PM EST  ALX Oncology Holdings Inc., (ALX Oncology) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today reported financial results for the third quarter ended September 30, 2021 and provided clinical development and operational highlights.   GlobeNewswire Inc
Nov 9, 2021
11:31AM EST  ALX Oncology Announces Updated Data From Ongoing Clinical Trial Of Evorpacept Showing Emerging Clinical Benefit In Survival-Based Endpoints In Patients With Advanced Solid Tumors   Benzinga
11:14AM EST  Shares of ALX Oncology Holdings Inc. (ALXO) slipped nearly 25% on Tuesday morning. The company announced updated data from an ongoing clinical trial of Evorpacept, which showed emerging clinical benefit in survival-based endpoints in patients with advanced solid tumors.   RTTNews
07:00AM EST  -- ORR of 72.2%, mDOR of 14.8 months, 12-month OS rate of 79%, and mOS of 17.1 months in Patients with >2L HER2 Positive Gastric/Gastroesophageal Junction Cancer --   GlobeNewswire Inc
Nov 2, 2021
09:00AM EDT  ALX Oncology Holdings Inc., (ALX Oncology) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that Jaume Pons, Ph.D., Founder, President and Chief Executive Officer and other senior executives, will participate in four upcoming virtual investor conferences.   GlobeNewswire Inc
Oct 21, 2021
12:11PM EDT  ALX Oncology Announces First Patient Dosed In ASPEN-05, A Phase 1/2 Study Of Evorpacept In Combination With Venetoclax And Azacitidine In Patients With Acute Myeloid Leukemia   Benzinga
07:00AM EDT  ALX Oncology Announces First Patient Dosed in ASPEN-05, a Phase   GlobeNewswire Inc
Oct 7, 2021
07:10AM EDT  ALX Oncology Holdings Acquires ScalmiBio For $4.5M In Cash And Will Make An Additional Payment Of $2M In Cash At The One-year Anniversary Of The Transaction Subject To Certain Conditions   Benzinga
07:00AM EDT  -- Acquisition adds novel and proprietary SHIELD platform for conditional activation of antibodies in tumor microenvironment and proprietary cytotoxic payloads for antibody drug conjugates -- Expands ALX Oncologys pipeline of drug candidates based on expertise in protein engineering and oncology   GlobeNewswire Inc
Oct 5, 2021
08:38AM EDT  Zymeworks : First Patient Dosed In Phase 1b/2 Trial Of Zanidatamab & Evorpacept In Breast Cancer And Other Solid Tumors   RTTNews
08:36AM EDT  Zymeworks And ALX Oncology Announce First Patient Dosed In Phase 1b/2 Clinical Trial Of Zanidatamab And Evorpacept (ALX148) In Patients With Advanced HER2-Expressing Breast Cancer And Other Solid Tumors   Benzinga
Oct 1, 2021
08:20AM EDT  ALX Oncology Announces 4 Abstracts Accepted For Presentation At Society For Immunotherapy Of Cancer 36th Annual Meeting On Nov. 10-14   Benzinga
08:00AM EDT  ALX Oncology Announces Four Abstracts Accepted for Presentation at   GlobeNewswire Inc
Sep 30, 2021
11:04AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For September 30, 2021   Benzinga
06:01AM EDT  A Peek Into The Markets: US Stock Futures Climb Ahead Of GDP, Jobless Claims Data   Benzinga
04:48AM EDT  Stifel Initiates Coverage On ALX Oncology Holdings with Buy Rating, Announces Price Target of $106   Benzinga
Sep 16, 2021
07:18AM EDT  ALX Oncology Begins Investigator-Sponsored Trial Of Evorpacept In Indolent And Aggressive Non-Hodgkin Lymphoma   RTTNews
07:01AM EDT  ALX Oncology Announces Initiation Of Investigator-Sponsored Trial of Evorpacept In Patients with Indolent And Aggressive Non-Hodgkin Lymphoma   Benzinga
07:00AM EDT  ALX Oncology Announces Initiation of Investigator-Sponsored Trial   GlobeNewswire Inc
Sep 14, 2021
07:01AM EDT  Lightstone Ventures Raises $375 Million Fund   PR Newswire
Sep 7, 2021
07:00AM EDT  ALX Oncology Holdings Inc., (ALX Oncology) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that Jaume Pons, Ph.D., Founder, President and Chief Executive Officer and other senior executives, will participate in two upcoming virtual investor conferences.   GlobeNewswire Inc
Aug 23, 2021
12:19PM EDT  So What's Going On With ALX Oncology's Stock?   Benzinga
Aug 12, 2021
04:22PM EDT  ALX Oncology Holdings Q2 EPS $(0.40) Down From $(0.22) YoY, Adj. Net Loss $14.037M vs Loss $10.698M In Same Qtr. Last Year   Benzinga
04:05PM EDT  ALX Oncology Holdings Inc., (ALX Oncology) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today reported financial results for the second quarter ended June 30, 2021 and provided clinical development and operational highlights.   GlobeNewswire Inc
Jul 28, 2021
08:50AM EDT  ALX Oncology Doses First Patient In ASPEN-04 For Patients With Advanced Head And Neck Squamous Cell Carcinoma   RTTNews
07:09AM EDT  ALX Oncology Announces First Patient Dosed in ASPEN-04, a Phase 2 Study of ALX148 in Combination with KEYTRUDA and Chemotherapy for the Treatment of Patients with Advanced Head and Neck Squamous Cell Carcinoma   Benzinga
07:00AM EDT  ALX Oncology Announces First Patient Dosed in ASPEN-04, a Phase 2   GlobeNewswire Inc
Jul 6, 2021
09:15AM EDT  ALX Oncology Shares Jump As ALX148 Shows ORR of 72% In Patients With HER2 Positive Stomach Cancer   Benzinga
09:14AM EDT  ALX Oncology On Saturday Announced New Data from ASPEN-01, the Phase 1b Study of ALX148, Showing Robust Objective Response in Patients with Gastric or Gastroesophageal Junction Cancer   Benzinga
Jul 3, 2021
07:15AM EDT  -- ORR of 72% Observed in Patients with >2L HER2 Positive Gastric or Gastroesophageal Junction Cancer-- Estimated OS at 12 months of 76%-- ALX Oncology to Host Conference Call on July 6th at 8:30 a.m. ET   GlobeNewswire Inc
Jun 14, 2021
07:02AM EDT  ALX Oncology Announces Update on ASPEN-03 and ASPEN-04, the ALX148 Phase 2 Head and Neck Cancer Studies   Benzinga
07:00AM EDT  --Interim report completed by ALX for a standard ongoing non-clinical safety study   GlobeNewswire Inc
Jun 11, 2021
08:05AM EDT  The Daily Biotech Pulse: Vertex Shelves Mid-Stage Study, Precigen & Novan Jump On Data, Hematology Conference, Janux Debuts   Benzinga
Jun 10, 2021
08:13AM EDT  The Daily Biotech Pulse: US To Procure 500M Pfizer-BioNTech Vaccine Doses For Donation, Verona Out-Licenses COPD Drug, Nautilus Lists Through SPAC Deal   Benzinga
07:30AM EDT  ALX Oncology Inks Clinical Trial Collaboration Supply Deal   RTTNews
07:07AM EDT  ALX Oncology Enters Clinical Trial Collaboration And Supply Agreement With Eli Lilly   RTTNews
07:02AM EDT  ALX Oncology Announces Clinical Trial Collaboration And Supply Agreement With Eli Lilly To Evaluate ALX148 Plus CYRAMZA, Trastuzumab And Paclitaxel; ALX To Conduct ALX148 Trial, Lilly To Supply Ramucirumab, Financial Terms Not Disclosed   Benzinga
07:00AM EDT  ALX Oncology to Collaborate with Lilly to Evaluate ALX148 Plus   GlobeNewswire Inc
May 18, 2021
07:00AM EDT  ALX Oncology Holdings Inc., (ALX Oncology) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that Jaume Pons, Ph.D., Founder, President and Chief Executive Officer and other senior executives, will participate in two upcoming virtual investor conferences.   GlobeNewswire Inc
May 17, 2021
04:20PM EDT  ALX Oncology Holdings Q1 EPS $(0.35) Up From $(2.37) YoY   Benzinga
04:05PM EDT  ALX Oncology Holdings Inc., (ALX Oncology) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today reported financial results for the first quarter ended March 31, 2021 and provided recent clinical development and operational highlights.   GlobeNewswire Inc
May 10, 2021
07:05AM EDT  ALX Oncology Announces First Patient Dosed in ASPEN-03, a Phase 2 Study of ALX148 in Combination with KEYTRUDA for the Treatment of Patients with Advanced Head and Neck Squamous Cell Carcinoma   Benzinga
07:00AM EDT  - The first of two distinct randomized Phase 2 studies in collaboration with Merckhas been initiated   GlobeNewswire Inc
Apr 21, 2021
04:05PM EDT  ALX Oncology to Present ALX148 Clinical Data at the ESMO 23rd   GlobeNewswire Inc
Apr 6, 2021
03:18PM EDT  ALX Oncology shares were trading higher after UBS initiated coverage on the stock with a Buy rating and a price target of $96 per share.   Benzinga
10:55AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For April 6, 2021   Benzinga
09:30AM EDT  UBS Initiates Coverage On ALX Oncology Holdings with Buy Rating, Announces Price Target of $96   Benzinga
Apr 5, 2021
07:00AM EDT  -- The post-grant review period for U.S. Patent 10,696,730 covering the composition of matter of ALX148 ended on March 30, 2021.   GlobeNewswire Inc
Mar 18, 2021
04:13PM EDT  ALX Oncology Holdings Q4 EPS $(0.50) Up From $(2.83) YoY   Benzinga
04:05PM EDT  ALX Oncology Holdings Inc., (ALX Oncology) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today reported financial results for the fourth quarter and year ended December 31, 2020 and provided clinical development and operational highlights.   GlobeNewswire Inc
Mar 15, 2021
07:14AM EDT  ALX Oncology Appoints Sophia Randolph To Board   RTTNews
07:00AM EDT  ALX Oncology Announces Appointment of Sophia Randolph, M.D.,   GlobeNewswire Inc
Mar 4, 2021
04:10PM EST  ALX Oncology And Tallac Therapeutics Announce Collaboration To Develop, Manufacture And Commercialize Novel Class Of Cancer Immunotherapeutics; Companies Will Share Equally In Cost OF R&D And Any Profits Or Losses Incurred   Benzinga
04:05PM EST  ALX Oncology and Tallac Therapeutics Announce Collaboration on   GlobeNewswire Inc
Mar 2, 2021
07:00AM EST  ALX Oncology to Participate at H.C. Wainwright Global Life   GlobeNewswire Inc
Feb 10, 2021
10:05AM EST  Benzinga's Top Ratings Upgrades, Downgrades For February 10, 2021   Benzinga
06:10AM EST  HC Wainwright & Co. Initiates Coverage On ALX Oncology Holdings with Buy Rating, Announces Price Target of $100   Benzinga
Jan 12, 2021
11:22PM EST  The lockup period of Burlingame, California-based ALX Oncology Holdings Inc. (ALXO) ends on January 13.   RTTNews
Jan 11, 2021
07:12AM EST  ALX Oncology Expects Cash to be Sufficient to Fund the Business Through 2024   Benzinga
07:12AM EST  ALX Oncology Provides Corporate Update And Highlights Key Milestones In 2021   RTTNews
07:00AM EST  ALX Oncology Holdings Inc., (ALX Oncology) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today provided a corporate update and highlighted key milestones anticipated in 2021.   GlobeNewswire Inc
Jan 5, 2021
07:00AM EST  ALX Oncology Holdings Inc., (ALX Oncology) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that Jaume Pons, Ph.D., Founder, President and Chief Executive Officer, will present a company overview at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12 at 10:50 am ET.   GlobeNewswire Inc
Dec 20, 2020
07:19AM EST  Notable Insider Buys of the Past Week: Mylan, Sonabank, Steak 'n Shake, U-Haul And More   Benzinga
Dec 17, 2020
07:03AM EST  ALX Oncology Added to the NASDAQ Biotechnology Index   Benzinga
07:00AM EST  ALX Oncology Holdings Inc., (ALX Oncology) (NASDAQ: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that it has been selected for addition to the NASDAQ Biotechnology Index (NASDAQ: NBI). ALXs addition to the NBI will become effective prior to market open on Monday, December 21, 2020.   GlobeNewswire Inc
Dec 14, 2020
04:05PM EST  ALX Oncology Announces Closing of Public Offering and Full   GlobeNewswire Inc
Dec 11, 2020
08:11AM EST  The Daily Biotech Pulse: Pfizer-BioNTech Receive FDA Panel Backing, Sanofi-GSK Disclose Delay In Vaccine Program, 4 Biotechs To Debut On Wall Street   Benzinga
Dec 10, 2020
07:42AM EST  The Daily Biotech Pulse: Key Vaccine Adcom Review For Pfizer-BioNTech, Puma, Immutep, G1 Rally On Breast Cancer Conference Presentations   Benzinga
05:49AM EST  ALX Oncology Priced Upsized 2.38M Share Public Offering of Common Stock @$76/Share   Benzinga
Dec 9, 2020
10:26PM EST  ALX Oncology Announces Pricing of Upsized Public Offering of   GlobeNewswire Inc
Dec 7, 2020
04:08PM EST  ALX Oncology Announces Proposed Public Offering of Common Stock   GlobeNewswire Inc
04:08PM EST  ALX Oncology Reports 2M Share Common Stock Offering   Benzinga
10:09AM EST  ALX Oncology Announces Updated Data From ASPEN-01, Ongoing Phase 1b Study Of ALX148, Showing Robust, Durable Activity In Patients With Non-Hodgkin Lymphoma   Benzinga
10:00AM EST  -- ORR of 70.0% Observed in Patients with NHL Treated with Higher Doses of ALX148 with Median Duration of Response Not Yet Reached   GlobeNewswire Inc
07:06AM EST  ALX Oncology Says the FDA Requested the Company Complete a Non-Clinical Safety Study to Increase Enrollment of its Two Phase 2 Studies Beyond 50 Participants   Benzinga
07:00AM EST  -- Due to the registration potential of two planned Phase 2 head and neck cancer studies, FDA has requested completion of a standard ongoing non-clinical safety study   GlobeNewswire Inc
Nov 24, 2020
08:13AM EST  The Daily Biotech Pulse: Alnylam's Oxluma Snags Early FDA Approval, DBV Chief Scientific Officer To Depart, Decision Day For Liquidia   Benzinga
07:00AM EST  ALX Oncology Holdings Inc., (ALX Oncology) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that Jaume Pons, Ph.D., Founder, President and Chief Executive Officer and other senior executives, will participate in two virtual investor conferences in December.   GlobeNewswire Inc
Nov 20, 2020
08:06AM EST  The Daily Biotech Pulse: Amarin Surges On Vascepa Data, Mesoblast Rallies On Novartis Deal, Decision Day For Eiger   Benzinga
Nov 18, 2020
07:30AM EST  The Daily Biotech Pulse: Kazia Jumps On Data Readout, Clinical Hold On Cellectis' Blood Cancer Study Lifted   Benzinga
Nov 17, 2020
08:32AM EST  The Daily Biotech Pulse: Setback For Alkermes, Boston Scientific's Recall, ALX-Zymeworks Oncology Collaboration   Benzinga
Nov 13, 2020
07:40AM EST  The Daily Biotech Pulse: Urovant In M&A Deal, Sanofi's Binary Event, Conference Presentations   Benzinga
Nov 12, 2020
04:14PM EST  ALX Oncology Holdings Q3 Net Loss $10.759M vs Loss $4.115M In Same Qtr. Last Year   Benzinga
Nov 9, 2020
08:21AM EST  ALX Oncology Announces New Data from ASPEN-01, the Phase 1b Study of ALX148, Showing Promising Initial Clinical Responses in Patients with Advanced Solid Tumors   Benzinga
08:10AM EST  -- ORR of 64% Observed in Patients with >2L HER2 Positive Gastric/Gastroesophageal Junction Cancer   GlobeNewswire Inc
Nov 8, 2020
03:58PM EST  The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions   Benzinga
12:47PM EST  The Week Ahead In Biotech: Earnings, Conference Presentations And IPOs   Benzinga
Nov 5, 2020
07:00AM EST  ALX Oncology Holdings Inc., (ALX Oncology) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint mechanism, today announced that both ALX148 clinical and preclinical results have been selected for presentation at the 62nd ASH Annual Meeting & Exposition, December 5-8, 2020.   GlobeNewswire Inc
Nov 2, 2020
07:00AM EST  ALX Oncology Holdings Inc., (ALX Oncology) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that Jaume Pons, Ph.D., Founder, President and Chief Executive Officer and other senior executives, will participate in two virtual investor conferences in November.   GlobeNewswire Inc
Oct 28, 2020
07:12AM EDT  ALX Oncology Announces First Patient Dosed in ASPEN-02, a Phase 1/2 Study of ALX148 in Combination with Azacitidine in Patients with Myelodysplastic Syndrome   Benzinga
07:00AM EDT  ALX Oncology Announces First Patient Dosed in ASPEN-02, a Phase   GlobeNewswire Inc
Oct 14, 2020
04:25PM EDT  ALX Oncology Holdings Inc., (ALX Oncology) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint mechanism, today announced that ALX148 clinical results have been selected for presentation at the SITC 35th Anniversary Annual Meeting, November 9 14, 2020.   GlobeNewswire Inc
Oct 6, 2020
07:00AM EDT  ALX Oncology Names Leading Oncology Experts to Scientific Advisory   GlobeNewswire Inc
Sep 22, 2020
07:02AM EDT  ALX Oncology To Collaborate With Merck On Phase 2 Immuno-Oncology Studies Evaluating ALX148, Targeting CD47, In Combination With KEYTRUDA In Patients With Head & Neck Cancer   Benzinga
07:00AM EDT  ALX Oncology to Collaborate with Merck on Phase 2 Immuno-Oncology   GlobeNewswire Inc
Sep 17, 2020
07:12AM EDT  ALX Oncology Added To Russell 2000 And 3000 Indexes   Benzinga
07:01AM EDT  ALX Oncology Added to Russell 2000 and   GlobeNewswire Inc
Sep 8, 2020
07:00AM EDT  ALX Oncology Holdings Inc., (ALX Oncology) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that Jaume Pons, Ph.D., President and Chief Executive Officer and other senior executives, will participate in two upcoming virtual investor conferences in September:   GlobeNewswire Inc
Aug 27, 2020
04:05PM EDT  Completed initial public offering of common stock on July 21, 2020, raising gross proceeds of $185.7 million   GlobeNewswire Inc
Aug 12, 2020
09:41AM EDT  Benzinga's Top Upgrades, Downgrades For August 12, 2020   Benzinga
Aug 11, 2020
07:23AM EDT  Cantor Fitzgerald Initiates Coverage On ALX Oncology Holdings with Overweight Rating, Announces Price Target of $64   Benzinga
05:47AM EDT  Piper Sandler Initiates Coverage On ALX Oncology Holdings with Overweight Rating, Announces Price Target of $55   Benzinga
05:46AM EDT  Jefferies Initiates Coverage On ALX Oncology Holdings with Buy Rating, Announces Price Target of $50   Benzinga
05:43AM EDT  Credit Suisse Initiates Coverage On ALX Oncology Holdings with Outperform Rating, Announces Price Target of $53   Benzinga
Jul 21, 2020
04:05PM EDT  ALX Oncology Announces Closing of Initial Public Offering and Full   GlobeNewswire Inc
Jul 20, 2020
05:11AM EDT  80 Biggest Movers From Friday   Benzinga
Jul 17, 2020
02:43PM EDT  Mid-Afternoon Market Update: Nasdaq Rises 40 Points; NIO Shares Plummet   Benzinga
12:00PM EDT  Mid-Day Market Update: Dow Falls 50 Points; ALX Oncology Shares Spike Higher   Benzinga
10:56AM EDT  ALX Oncology Shares Open For Trade At $36.50; IPO Priced At $19/Share   Benzinga
10:47AM EDT  ALX Oncology Shares Indicated $35 On 174K Shares   Benzinga
10:37AM EDT  ALX Oncology Shares Indicated $35.50   Benzinga
10:27AM EDT  ALX Oncology Shares Indicated To Open At $37.05   Benzinga
09:45AM EDT  IPOs For July 17, 2020: Renalytix AI, Pandion Therapeutics, Deerfield Healthcare Technology, ALX Oncology And Berkeley Lights   Benzinga
08:44AM EDT  ALX Oncology Holdings Expected To Quote At 10:10 a.m. EDT; Expected To Open For Trade After 10:20 EDT; IPO Priced At $19/Share   Benzinga
05:55AM EDT  ALX Oncology Prices 8.5M Share IPO @$19/Share   Benzinga
Jul 16, 2020
08:49PM EDT  ALX Oncology Prices IPO Of 8.50 Mln Shares At $19.00/shr   RTTNews
08:39PM EDT  ALX Oncology Announces Pricing of Initial Public Offering   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC